---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-025159"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2025-11-26T23:59:59+00:00"
generated_at: "2026-05-16T16:21:50.435456+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics receives Nasdaq delisting notice for equity and filing non-compliance

## Summary
- Stockholders' equity fell below $2.5M minimum per Listing Rule 5550(b)(1) as of June 30, 2025.
- Company also cited for delayed Form 10-Q for quarter ended September 30, 2025 (Rule 5250(c)(1)).
- Will request hearing before Nasdaq Hearings Panel; automatic 15-day stay of suspension granted.
- Common stock and warrants will continue trading on Nasdaq during automatic stay and any extended stay.
- Company expects to file the overdue 10-Q imminently but no assurance Panel will grant relief.

## SEC filing metadata
- accession: 0001493152-25-025159
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2025-11-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000149315225025159/0001493152-25-025159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000149315225025159/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-025159
- JSON: https://secwatch.observer/filing/0001493152-25-025159.json
- Plain text: https://secwatch.observer/filing/0001493152-25-025159.txt

## Key facts
- Listing & Compliance Notices
  Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: November 20, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter (the “Notice” ) from the Nasdaq Listing Qualifications Staff (the “Staff” ) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Compa
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000149315225025159/0001493152-25-025159-index.htm
- Listing & Compliance Notices
  Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: November 20, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter (the “Notice” ) from the Nasdaq Listing Qualifications Staff (the “Staff” ) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Compa
  evidence_url: https://www.sec.gov/Archives/edgar/data/1022899/000149315225025159/0001493152-25-025159-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.